3.20% 0.00775

Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1163)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CTOR's Discussions on Twitter

Vergleichen Sie CTOR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTOR Citius Oncology Inc	0.6178	43.65M	0	0	0	0.00
ZTS Zoetis Inc	162.58	72.71B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.26	48.03B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.33	46.73B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.05	18.42B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.54	13.99B	612.78M	-86.37M	-62.91M	-0.87

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-27	Eingeleitet	Maxim Group	Buy

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Es liegen keine Finanzdaten für Citius Oncology Inc (CTOR) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Vergleichen Sie CTOR mit anderen Aktien

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - Simply Wall St

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financia - GuruFocus.com

Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN

Citius Oncology (NASDAQ:CTOR) Issues Earnings Results - MarketBeat

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - 69News WFMZ-TV

Citius Oncology Inc. (CTOR) reports earnings - Quartz

CITIUS ONCOLOGY, INC. SEC 10-Q Report - TradingView

Citius Oncology Preps LYMPHIR Cancer Drug Launch While Strategic Review Unfolds - StockTitan

Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan

Citius Pharmaceuticals (NASDAQ:CTXR) Announces Issuance of Permanent J-Code for LYMPHIR by CMSOn February 6, 2025, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) disclosed in an 8-K filing that the company and its oncology subsidiary, Citius Oncol - Defense World

Citius Pharma’s LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Nigeria

Citius Pharma's LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Australia

Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance CodeMajor Win for CTCL Patients - StockTitan

Citius Oncology (NASDAQ:CTOR) Shares Down 2%Here's What Happened - MarketBeat

Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - 69News WFMZ-TV

Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - BioSpace

Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire

Citius Oncology to explore strategic alternatives - Yahoo Finance

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve

Citius Oncology Explores Strategic Options with Jefferies Following LYMPHIR FDA Approval - StockTitan

Citius Pharma Reports 2024 Financial Results and Business Update - MSN

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance

Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com

Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz

Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com

Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online

“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart

“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch” - Financial Content

Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World

Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St

Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com

Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com

Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan

CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada

CTOR stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CTOR